Dako said this week that it has gained CE-marking for the use of its HercepTest and HER2 FISH pharmDx tests in metastatic stomach cancer patients who may benefit from Herceptin treatment.
The CE-marking is based on the results of a study of more than 3,700 patients that showed that treatment with Herceptin significantly prolonged the lives of patients with metastatic HER2-positive stomach cancer detected via Dako's tests.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
